Want to see SE:FLUO full AI Analyst Report?
Top Page
FluoGuide A/S
(FLUO)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr30.00
▼(-3.23% Downside)
Action:Reiterated
Date:08/27/26
The score is held down primarily by very weak financial performance—minimal revenue, large ongoing losses, and heavy cash burn—along with rising leverage. Technicals add further pressure as the stock trades below major moving averages with negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and there is no dividend yield data.
Positive Factors
Focused Oncology Imaging Platform
The company targets a clear surgical need: improving tumor visualization while sparing healthy tissue. A focused oncology imaging platform could support differentiated clinical value if FG001 demonstrates efficacy and gains regulatory approval.
Negative Factors
Minimal and Declining Revenue
Very limited and declining revenue shows that the business has not yet established commercial scale. This leaves results dependent on clinical execution and future approvals, increasing the risk that operating costs will remain unsupported.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Oncology Imaging Platform
The company targets a clear surgical need: improving tumor visualization while sparing healthy tissue. A focused oncology imaging platform could support differentiated clinical value if FG001 demonstrates efficacy and gains regulatory approval.
Read all positive factors
FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr546.07M
Dividend YieldN/A
Average Volume (3M)8.21K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue GrowthN/A
EPS Growth-23.57%
CountrySE
Employees7
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.00
Shares Outstanding16,349,314
10 Day Avg. Volume11,579
30 Day Avg. Volume8,206
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)6.10
Price to Sales (P/S)0.00
P/FCF Ratio-8.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.03
Revenue Forecast (FY)N/A
FluoGuide A/S Business Overview & Revenue Model
Company Description
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grad...
How the Company Makes Money
FluoGuide’s business model is centered on developing proprietary fluorescence imaging agents and monetizing them through (1) future commercial sales (if/when regulatory approvals are obtained) and/or (2) partnering and licensing transactions with ...
FluoGuide A/S Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 54.00K | 0.00 | 385.00K | 423.00K | 6.51M | 9.61M |
| Gross Profit | -416.92K | -571.17K | 385.00K | 423.00K | 6.51M | 9.61M |
| EBITDA | -48.08M | -40.42M | -32.81M | -43.90M | -32.21M | -28.65M |
| Net Income | -46.24M | -40.39M | -28.96M | -38.38M | -27.34M | -23.77M |
Balance Sheet | ||||||
| Total Assets | 65.25M | 88.34M | 28.38M | 29.61M | 35.62M | 53.31M |
| Cash, Cash Equivalents and Short-Term Investments | 49.92M | 78.84M | 18.61M | 21.67M | 26.01M | 46.76M |
| Total Debt | 27.56M | 28.30M | 624.00K | 10.83M | 205.00K | 57.00K |
| Total Liabilities | 34.51M | 33.78M | 5.31M | 16.89M | 3.65M | 14.61M |
| Stockholders Equity | 30.74M | 54.56M | 23.07M | 12.72M | 31.97M | 38.70M |
Cash Flow | ||||||
| Free Cash Flow | -44.28M | -37.83M | -30.00M | -31.81M | -37.71M | -15.06M |
| Operating Cash Flow | -43.80M | -37.83M | -29.15M | -31.81M | -37.65M | -15.06M |
| Investing Cash Flow | -30.37M | -30.61M | -987.00K | -37.00K | -117.00K | 0.00 |
| Financing Cash Flow | 74.76M | 99.33M | 27.08M | 27.50M | 17.02M | 51.18M |
FluoGuide A/S Technical Analysis
Negative
31.00
Price Trends
35.35
Negative
38.81
Negative
37.49
Negative
Market Momentum
-0.71
Negative
41.69
Neutral
30.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Negative. The current price of 31 is below the 20-day moving average (MA) of 31.80, below the 50-day MA of 35.35, and below the 200-day MA of 37.49, indicating a bearish trend. The MACD of -0.71 indicates Negative momentum. The RSI at 41.69 is Neutral, neither overbought nor oversold. The STOCH value of 30.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLUO.
FluoGuide A/S Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | kr129.96M | -1.24 | -81.76% | ― | 55.24% | 70.00% | |
48 Neutral | kr91.81M | -2.43 | -120.70% | ― | -97.37% | 25.28% | |
47 Neutral | kr47.53M | -20.57 | -45.97% | ― | 573.00% | 80.00% | |
45 Neutral | kr629.66M | -1.81 | ― | ― | 109.22% | 27.30% | |
44 Neutral | kr1.60B | -4.62 | -53.88% | ― | 258.30% | 28.33% | |
41 Neutral | kr546.07M | -6.97 | ― | ― | ― | -23.57% |
* General Sector Average
SE:FLUO
FluoGuide A/S
31.00
-9.90
-24.21%
SE:BINV
BioInvent International AB
23.50
-8.25
-25.98%
SE:ONCO
Oncopeptides AB
1.70
-3.16
-64.97%
SE:BIOVIC.B
Biovica International AB Class B
0.45
-0.20
-30.75%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.06
-35.59%
SE:FLUI
Fluicell AB
35.10
25.15
252.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.